Ginkgo Bioworks Holdings

Ginkgo Bioworks is a cell-engineering and synthetic-biology platform company that programs cells and builds the data, software and automation infrastructure around them. Its Ginkgo Datapoints offering generates biology-scale datasets — functional genomics, antibody developability and small-molecule developability — formatted for machine-learning consumption, and supplies them into third-party AI drug-discovery networks. The company runs large-scale autonomous laboratory infrastructure, including a cloud-accessible lab interface, and sells cell-engineering research and development services across pharmaceutical, biotechnology, agriculture, industrial, food and nutrition, and government customers. Ginkgo completed the divestiture of its biosecurity segment in 2026 and has concentrated its investment on autonomous labs, AI-ready biological data and cost-competitive contract research services.